Otsuka Holdings Co., Ltd.

4578

JP3188220002

Pharmaceuticals

Delayed Japan Exchange Other stock markets 06:30:00 10/02/2026 GMT			5-day change	1st Jan Change
9,857.00 ^JPY	+2.56%		+5.15%	+11.09%

02-04	Biodexa announces exclusive license of Otsuka's OPB-171775, a potent phase 1 ready molecular glue for GIST	RE
02-04	HBM Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2025	CI

Otsuka Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025

Published on 07/31/2025 at 05:30 am BST

S&P Capital IQ

OTSUKA HOLDINGS CO., LTD.

+2.56%

Otsuka Holdings Co., Ltd. reported earnings results for the half year ended June 30, 2025. For the half year, the company reported sales was JPY 1,180,766 million compared to JPY 1,108,930 million a year ago. Basic earnings per share from continuing operations was JPY 326.12 compared to JPY 198.61 a year ago.

Latest news about Otsuka Holdings Co., Ltd.

02-04	Biodexa announces exclusive license of Otsuka's OPB-171775, a potent phase 1 ready molecular glue for GIST	RE
02-04	HBM Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2025	CI
02-02	Otsuka Corporation Provides Dividend Guidance for the Second Quarter End of Fiscal Year Ending March 31, 2026	CI
02-02	Otsuka Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026	CI
01-27	Cms announces selection of drugs for third cycle of the Medicare drug price negotiation program	RE
01-22	Vertex Pharmaceuticals Poised for Higher Valuation on Povetacicept, Cystic Fibrosis Pipeline, RBC Says	MT
01-12	Ionis Pharmaceuticals, Inc. Provides Additional Updates on Key Milestones Expected in 2026	CI
11-26	Otsuka Wins U.S. FDA Accelerated Approval for VOYXACT	MT
11-25	Otsuka Holdings Co receives FDA accelerated approval for Voyxact for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression	RE
11-25	Fda approves use of Voyxact to reduce proteinuria in primary immunoglobulin	RE
11-25	US FDA approves Otsuka's drug for a type of kidney disease	RE
11-14	Ema's CHMP announces positive recommendation on extension of therapeutic indications for Koselugo	RE
11-10	Japanese Shares Rise as U.S. Shutdown Deal Nears	MT
11-10	Otsuka Pharmaceutical, Co. Ltd. Announces Findings from 12-Month Interim Analysis of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults	CI
11-10	Otsuka's Sibeprenlimab Shows 54% Reduction in Proteinuria in Phase 3 IgAN Trial	MT
31/10/25	4D Molecular Shares Rise Premarket on Partnership With Otsuka	DJ
31/10/25	Otsuka Holdings Nine-Month Profit Rises 55%	MT
31/10/25	Otsuka Holdings Co., Ltd. Reaffirms Consolidated Financial Forecast for the Fiscal Year Ending December 31, 2025	CI
01/10/25	Nikkei ends at three-week low on profit-taking as second half of fiscal year begins	RE
01/10/25	Nikkei falls on profit-taking at start of second half of fiscal year	RE
26/09/25	Japan's Topix posts record-high close despite US tariffs on pharma	RE
26/09/25	Japan's Topix hits record high despite US tariffs on pharma	RE
22/09/25	Otsuka Completes Transfer of MicroPort Stake Held By Medical Devices Unit	MT
22/09/25	Otsuka Pharmaceutical Co., Ltd. Receives Complete Response Letter from U.S. FDA for sNDA of REXULTI (Brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder	CI
22/09/25	US FDA Rejects Otsuka and Lundbeck's PTSD Drug Application	MT

Chart Otsuka Holdings Co., Ltd.

Duration

Period

4578: Dynamic Chart

Company Profile

Otsuka Holdings Co Ltd is a Japan-based company mainly engaged in medical, nutraceutical, consumer and other business activities in Japan and overseas. The Company operates in four business segments. The Medical Business segment produces and sells therapeutic drugs and infusions. The Nutraceutical segment produces and sells functional beverages, quasi-drugs and nutritional supplements. The Consumer Products segment produces and sells mineral water, beverages and food products. The Others segment manufactures paper containers, manufactures synthetic resin molded products, stores products, provides storage space, and produces and sells chemicals and liquid crystal evaluation equipment, spectroscopic analysis equipment, and other products.

Employees

35,338

Sector

Pharmaceuticals

Calendar

02-12 - Q4 2025 Earnings Release

More about the company